Janux Shares Surge on Promising JANX007 Prostate Cancer Trial

On Monday, Janux Therapeutics, Inc. (NASDAQ:JANX) experienced a significant increase in its stock value, rising by 54% following the announcement of positive interim clinical data for its prostate cancer drug candidate, JANX007. The data revealed a promising efficacy and safety profile in a Phase 1a dose escalation study for patients with metastatic castration-resistant prostate cancer (mCRPC).

The clinical trial results indicated that JANX007 demonstrated notable clinical activity in patients who had previously undergone extensive treatments, referred to as the 5L mCRPC cohort. Specifically, a reduction of 50% or more in prostate-specific antigen (PSA) levels, a key marker for prostate cancer, was observed in all patients included in the study. Additionally, 63% of patients showed a 90% decrease in PSA levels, while 31% exhibited a 99% decrease.

The treatment also displayed durability; 75% of patients maintained a 50% reduction in PSA levels for 12 weeks or longer, while half of the patients sustained a 90% reduction over the same period. The drug was well-tolerated by patients, with the majority of reported side effects being manageable and primarily occurring during the initial treatment cycle.

The promising data supports Janux's clinical development strategy, and the company aims to expand its trials to include patients who have not yet received PLUVICTO® treatment. PLUVICTO® is a therapy for mCRPC. The company has established a two-week titration dosing regimen for Phase 1b expansion trials targeting these pre-PLUVICTO® patients in the second and third lines of treatment.